Dengue

Current Opinion in Infectious Diseases

Volumn 15, Issue 5, 2002, Pages 471-476

  Halstead, Scott B ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Dengue; Dengue hemorrhagic fever; Diagnosis; Flaviviruses; HLA; Treatment; Viral hemorrhagic fever

Indexed keywords

LEUKOCYTE ANTIGEN; SODIUM CHLORIDE; VIRUS RNA;

AEDES AEGYPTI; CLINICAL FEATURE; COLLOID; DENGUE; DENGUE VIRUS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISSEMINATED INTRAVASCULAR CLOTTING; EARLY DIAGNOSIS; EPIDEMIC; FLUID THERAPY; GENE IDENTIFICATION; HUMAN; INFECTION SENSITIVITY; INTENSIVE CARE; PATHOGENESIS; PATHOPHYSIOLOGY; PROTECTION; PULSE PRESSURE; RACE DIFFERENCE; REVIEW; SERODIAGNOSIS; SHOCK; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT INDICATION; VIRUS CARRIER; VIRUS GENE; VIRUS REPLICATION; IMMUNOLOGY; PATHOGENICITY; PHYSIOLOGY;

DENGUE; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; HUMANS;

EID: 0036791267     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200210000-00003     Document Type: Review

References (40)

1. O'Brien D, Tobin S, Brown GV, Torresi J. Fever in returned travelers: review of hospital admissions for a 3-year period. Clin Infect Dis 2001; 33:603-609.
2. Radakovic-Fijan S, Graninger W, Muller C, et al. Dengue hemorrhagic fever in a British travel guide. J Am Acad Dermatol 2002; 46:430-433.
3. Technical Guide. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: World Health Organization; 1997.
4. Cao XT, Ngo TN, Wills B, et al. Evaluation of the World Health Organization standard tourniquet test and a modified tourniquet test in the diagnosis of dengue infection in Viet Nam. Trop Med Int Health 2002; 7:125-132.
5. Pea L, Roda L, Moll F. Desmopressin treatment for a case of dengue hemorrhagic fever/dengue shock syndrome. Clin Infect Dis 2001; 33:1611-1612.
6. Gomber S, Ramachandran VG, Kumar S, et al. Hematological observations as diagnostic markers in dengue hemorrhagic fever: a reappraisal. Indian Pediatr 2001; 38:477-481.
7. Lum LC, Goh AY, Keong Chan PW, et al. Risk factors for hemorrhage in severe dengue infections. J. Pediatr 2002; 140:629-631.
8. Krishnamurti C, Kalayanarooj S, Cutting MA, et al. Mechanisms of hemorrhage in dengue without circulatory collapse. Am J Trop Med Hyg 2001; 65:840-847.
9. Strobel M, Muller P, Lamaury I, Rouet F. Dengue fever: a harmful disease in patients with thrombocytopenia? Clin Infect Dis 2001; 33:580-581.
10. Lin CF, Lei HY, Liu CC, et al. Generation of IgM anti-platelet autoantibody in dengue patients. J Med Virol 2001; 63:143-149.
11. Soni A, Chugh K, Sachdev A, Gupta D. Management of dengue fever in ICU. Indian J Pediatr 2001; 68:1051-1055.
12. Ngo NT CX, Kneen R, Wills B, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001; 32:204-213.
13. Bethell DB, Gamble J, Pham PL, et al. Noninvasive measurement of microvascular leakage in patients with dengue hemorrhagic fever. Clin Infect Dis 2001; 32:243-253.
14. Cam BV, Fonsmark L, Hue NB, et al. Prospective case-control study of encephalopathy in children with dengue hemorrhagic fever. Am J Trop Med Hyg 2001; 65:848-851.
15. Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185:1213-1221.
16. Zinkernagel RM. Protective antibody responses against viruses. Biol Chem 1997; 378:725-729.
17. Halstead SB, Streit TG, Lafontant JG, et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 2001; 65:180-183.
18. Loke H, Bethell DB, Phuong CX, et al. Strong HLA class I-restricted T cell responses in dengue hemorrhagic fever: a double-edged sword? J Infect Dis 2001; 184:1369-1373.
19. Zivna I, Green S, Vaughn DW, et al. T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol 2002; 168:5959-5965.
20. Juffrie M, Meer GM, Hack CE, et al. Inflammatory mediators in dengue virus infection in children: interleukin-6 and its relation to C-reactive protein and secretory phospholipase A2. Am J Trop Med Hyg 2001; 65:70-75.
21. Bethell DB, Flobbe K, Cao XT, et al. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis 1998; 177:778-782.
22. Murgue B, Cassar O, Deparis X. Plasma concentrations of sVCAM-1 and severity of dengue infections. J Med Virol 2001; 65:97-104.
23. Gagnon SJ, Leporati A, Green S, et al. T cell receptor Vbeta gene usage in Thai children with dengue virus infection. Am J Trop Med Hyg 2001; 64:41-48.
24. Gagnon SJ, Mori M, Kurane I, et al. Cytokine gene expression and protein production in peripheral blood mononuclear cells of children with acute dengue virus infections. J Med Virol 2002; 67:41-46.
25. Wu SJ, Grouard-Vogel G, Sun W, et al. Human skin Langerhans cells are targets of dengue virus infection [see comments]. Nat Med 2000; 6:816-820.
26. Ho LJ, Wang JJ, Shaio MF, et al. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol 2001; 166:1499-1506.
27. Libraty DH, Pichyangkul S, Ajariyakhajorn C, et al. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol 2001; 75:3501-3508.
28. Marovich J, Grouard-Vogel G, Louder J, et al. Human dendritic cells as targets of dengue virus infection. J. Investig Dermatol Symp Proc 2001; 6:219-224.
29. Marks RM, Lu H, Sundaresan R, et al. Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. J Med Chem 2001; 44:2178-2187.
30. Thullier P, Demangel C, Bedouelle H, et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 2001; 82:1885-1892.
31. Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001; 75:7769-7773.
32. Martinez-Barragan JJ, del Angel RM. Identification of a putative coreceptor on Vero cells that participates in dengue 4 virus infection. J Virol 2001; 75:7818-7827.
33. Bielefeldt-Ohmann H, Meyer M, Fitzpatrick DR, Mackenzie JS. Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains. Virus Res 2001; 73:81-89.
34. Nawa M, Takasaki T, Yamada KI, et al. Development of dengue IgM-capture enzyme-linked immunosorbent assay with higher sensitivity using monoclonal detection antibody. J Virol Methods 2001; 92:65-70.
35. Cardosa MJ, Want SM, Sukm MSH, Tio PH. Antibodies against prM protein distinguish between previous infection with dengue and Japanese encephalitis viruses. BMC Microbiol 2002; 2:1-9.
36. Houng HS, Chung-Ming Chen R, Vaughn DW, Kanesa-thasan N. Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3′ noncoding sequences. J Virol Methods 2001; 95:19-32.
37. Wu SJ, Lee EM, Putvatana R, et al. Detection of dengue viral RNA using a nucleic acid sequence-based amplification assay. J Clin Microbiol 2001; 39:2794-2798.
38. Bagnis C, Chabannon C, Mannoni P. Beta-galactosidase marker genes to tag and track human hematopoietic cells. Cancer Gene Ther 1999; 6:3-13.
39. Sudiro TM, Zivny J, Ishiko H, et al. Analysis of plasma viral RNA levels during acute dengue virus infection using quantitative competitor reverse transcription-polymerase chain reaction. J Med Virol 2001; 63:29-34.
40. Pryor MJ, Gualano RC, Lin B, et al. Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus-encoded glycoproteins. J Gen Virol 1998; 79:2631-2639.